Cardiac complications during DLBCL treatment using R-CHOP

• Authors: Barbara Sosnowska-Pasiarska , Paweł Zgódka , Paulina Steckiewicz , Marcin Pasiarski
• Languages of publication: EN

Abstracts

EN

Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.

Keywords

EN

DLBCL; implantable cardioverter-defibrillator; rituximab; sudden cardiac arrest

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2019
• Volume: 9
• Issue: 1
• Pages: 22-26

Contributors

author

Barbara Sosnowska-Pasiarska

• Department of Oncocardiology, Holy Cross Cancer Center, Kielce

author

Paweł Zgódka

• Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce

author

Paulina Steckiewicz

• Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce

author

Marcin Pasiarski

• Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce. The Faculty of Medicine and Health Sciences, The Jan Kochanowski University, Kielce

References

• 1. Li S, Young KH, Mederidos LJ. Diffuse large B-cell lymphoma. Pathology 2018; 50: 74-87.
• 2. Ziepert M, Hasenclever D, Kuhnt E et al. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 B-Cell Lymphoma in the Rituximab Era. J Clin Oncol 2010; 28: 14.
• 3. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010; 9: 116.
• 4. Martelli M, Ferreri AJM, Agostinelli C et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171.
• 5. Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011; 29: 174-185.
• 6. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
• 7. Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-Induced Polymorphic Ventricular Tachycardia. Tex Heart Inst J 2010; 37(2): 218-220.
• 8. Lee L, Kukreti V. Rituximab-Induced Coronary Vasospasm. Case Rep Hematol 2012. Article ID 984986. DOI:10.1155/2012/984986.
• 9. Ke C, Khosla A, Davis MK et al. A Case of Coronary Vasospasm after Repeat Rituximab Infusion. Case Rep Cardiol 2015. Article ID 523149. http://dx.doi.org/10.1155/2015/523149.
• 10. Naqvi SY, Hanley A, Crowley J. Ventricular fibrillation due to coronary vasospasm. BMJ Case Rep 2014. DOI:10.1136/bcr-2013-203253.
• 11. Arenja N, Zimmerli L, Urbaniak P, Vogel R. Acute anterior myocardial infarction after rituximab. Dtsch Med Wochenschr 2016; 141: 500-503. DOI: 10.1055/s-0041-106055.
• 12. Bambury R, Gallagher F, Dodd JD, Fennelly D. Primary cardiac lymphoma: diagnostic tools and treatment challenges. Ir J Med Sci 2011; 180: 271-273. DOI: 10.1007/s11845-009-0446-x.
• 13. Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep 2015. DOI:10.1136/bcr2014-208203.
• 14. Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol 2005; 78: 316-319. https://doi.org/10.1002/ajh.20303.
• 15. Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005; 72: 165-175.
• 16. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-174.

• Document Type: undetermined